These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 33237566)

  • 1. Filgotinib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2020 Dec; 80(18):1987-1997. PubMed ID: 33237566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
    Kim ES; Keam SJ
    Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
    Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
    Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
    van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
    Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Filgotinib as rheumatoid arthritis therapy.
    Becciolini A; Di Donato E; Santilli D; Lucchini G; Mozzani F; Riva M; Ariani A
    Drugs Today (Barc); 2021 Sep; 57(9):543-550. PubMed ID: 34586102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
    Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
    JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Filgotinib for the treatment of rheumatoid arthritis.
    Taylor PC; Abdul Azeez M; Kiriakidis S
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1181-1187. PubMed ID: 28838249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
    Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
    Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating filgotinib for the treatment of rheumatoid arthritis.
    Richez C; Truchetet ME
    Expert Opin Pharmacother; 2021 Dec; 22(18):2435-2444. PubMed ID: 34402699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
    Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
    Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Song GG
    Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis.
    Nakayamada S; Kubo S; Iwata S; Tanaka Y
    BioDrugs; 2016 Oct; 30(5):407-419. PubMed ID: 27577235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
    Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
    Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
    Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes.
    Genovese M; Westhovens R; Meuleners L; Van der Aa A; Harrison P; Tasset C; Kavanaugh A
    Arthritis Res Ther; 2018 Mar; 20(1):57. PubMed ID: 29566740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MANTA and MANTA-RAy: Rationale and Design of Trials Evaluating Effects of Filgotinib on Semen Parameters in Patients with Inflammatory Diseases.
    Hellstrom WJG; Dolhain RJEM; Ritter TE; Watkins TR; Arterburn SJ; Dekkers G; Gillen A; Tonussi C; Gilles L; Oortwijn A; Van Beneden K; de Vries DE; Sikka SC; Vanderschueren D; Reinisch W
    Adv Ther; 2022 Jul; 39(7):3403-3422. PubMed ID: 35614292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of filgotinib in Japanese patients with refractory rheumatoid arthritis: Subgroup analyses of a global phase 3 study (FINCH 2).
    Takeuchi T; Matsubara T; Atsumi T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Genovese MC; Kalunian K; Walker D; Gottenberg JE; de Vlam K; Bartok B; Pechonkina A; Kondo A; Gao J; Guo Y; Tasset C; Sundy JS; Tanaka Y
    Mod Rheumatol; 2022 Jan; 32(1):59-67. PubMed ID: 33274687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.